Therapy Detail

Therapy Name Gemcitabine
Therapy Description

Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Gemcitabine Gemzar Difluorodeoxycytidine Hydrochlorothiazide Chemotherapy - Antimetabolite 10 Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
SMAD4 del pancreatic cancer decreased response Gemcitabine Preclinical Actionable In a preclinical study, pancreatic cancer cell lines harboring SMAD4 homozygous deletions were half as sensitive to gemcitabine in vitro as wild-type cells (PMID: 22753594). 22753594
Clinical Trial Phase Therapies Title Recruitment Status
NCT03770299 Phase II Docetaxel Nivolumab Paclitaxel Cisplatin Carboplatin Gemcitabine Pemetrexed Vinorelbine An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease (CheckMate 9TN) Not yet recruiting
NCT01013649 Phase II Erlotinib + Gemcitabine Gemcitabine Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery Active, not recruiting
NCT01164228 Phase II Sunitinib Gemcitabine Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery Active, not recruiting
NCT02477826 Phase III Nivolumab Cisplatin Ipilimumab Pemetrexed Carboplatin Gemcitabine An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC) Recruiting
NCT01248949 Phase I Bevacizumab MEDI3617 Gemcitabine Carboplatin Paclitaxel A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors Completed
NCT02399137 Phase II nab-paclitaxel Gemcitabine MM-141 A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer Completed
NCT03819465 Phase I Gemcitabine Durvalumab + Oleclumab Carboplatin Pemetrexed nab-paclitaxel AZD9150 + Durvalumab Cisplatin Durvalumab A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN) Recruiting
NCT01497392 Phase I Gemcitabine Dovitinib Capecitabine Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers Completed
NCT01858883 Phase I nab-paclitaxel Filgrastim Itacitinib Gemcitabine Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors Completed
NCT02365766 Phase Ib/II Cisplatin Pembrolizumab Gemcitabine Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer Recruiting
NCT01879085 Phase Ib/II Gemcitabine Docetaxel Pegfilgrastim Vorinostat Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma Recruiting
NCT02621151 Phase II Pembrolizumab Gemcitabine Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder Recruiting
NCT02237157 Phase I Gemcitabine A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer Active, not recruiting
NCT03563144 Phase II Gemcitabine Nab-paclitaxel + Gemcitabine NANT pancreatic cancer vaccine combination QUILT-3.088: NANT Pancreatic Cancer Vaccine Not yet recruiting
NCT01586611 Phase III Gemcitabine Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer Unknown status
NCT01945775 Phase III Gemcitabine Capecitabine Vinorelbine Talazoparib Eribulin A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Active, not recruiting
NCT02138383 Phase I Enzalutamide nab-paclitaxel Gemcitabine Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer Active, not recruiting
NCT01454102 Phase I Bevacizumab Ipilimumab Cisplatin Pemetrexed Gemcitabine Erlotinib Carboplatin Paclitaxel Nivolumab Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) Active, not recruiting
NCT02117024 Phase II HS-110 + Cyclophosphamide Pemetrexed Vinorelbine Erlotinib Gemcitabine Docetaxel Paclitaxel A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer Active, not recruiting
NCT02312245 Phase II Topotecan Doxorubicin Paclitaxel Gemcitabine Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting
NCT00936936 Phase II Gemcitabine Ifosfamide Etoposide Melphalan Etoposide + Ifosfamide Docetaxel + Gemcitabine + Melphalan Bevacizumab + Carboplatin High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors Active, not recruiting
NCT02631876 Phase II Doxil + Paclitaxel Gemcitabine Topotecan Mirvetuximab Soravtansine PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer Active, not recruiting
NCT02574078 Phase I nab-paclitaxel Crizotinib Bevacizumab + Pemetrexed Paclitaxel Docetaxel Nivolumab Pemetrexed Gemcitabine Erlotinib Carboplatin A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370) Active, not recruiting
NCT02788201 Phase II Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifine Crizotinib Dactinomycin Temsirolimus Vorinostat romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma Recruiting
NCT00565851 Phase III Gemcitabine Docetaxel + Paclitaxel Carboplatin Bevacizumab Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Active, not recruiting
NCT02565758 Phase I Gemcitabine Nivolumab nab-paclitaxel ABBV-085 ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors Active, not recruiting
NCT01908478 Phase I Veliparib Gemcitabine A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer Active, not recruiting
NCT01647828 Phase Ib/II nab-paclitaxel Gemcitabine Tarextumab A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer Completed
NCT02322281 Phase III Pemetrexed Gemcitabine Paclitaxel Docetaxel Rociletinib TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy Terminated
NCT02275039 Phase I MVAp53 Gemcitabine p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer Completed
NCT01959672 Phase II Nelfinavir Oregovomab Fluorouracil + Leucovorin Gemcitabine Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer Active, not recruiting
NCT02620423 Phase I Gemcitabine Fluorouracil Irinotecan Reolysin Leucovorin Pembrolizumab Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma Completed
NCT03137771 Phase II Docetaxel Pemetrexed Gemcitabine Erlotinib Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer Recruiting
NCT02157792 Phase I Cisplatin Etoposide VX-970 Gemcitabine An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy Recruiting
NCT02041533 Phase III Nivolumab Paclitaxel Cisplatin Pemetrexed Carboplatin Gemcitabine An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Active, not recruiting
NCT02855944 Phase III Cisplatin Rucaparib Carboplatin Gemcitabine Paclitaxel ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Recruiting
NCT02437370 Phase I Pembrolizumab Gemcitabine Docetaxel Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer Recruiting
NCT02265510 Phase I Gemcitabine Carfilzomib Dexamethasone Lenalidomide nab-paclitaxel Azacitidine INCB052793 Bortezomib An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies Active, not recruiting
NCT02194829 Phase Ib/II Paclitaxel Gemcitabine Adavosertib Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery Active, not recruiting
NCT02576574 Phase III Gemcitabine Paclitaxel Cisplatin Avelumab Pemetrexed Carboplatin Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100) Active, not recruiting
NCT03432741 Phase I Carfilzomib Daratumumab Obinutuzumab Gemcitabine Trastuzumab romidepsin Nivolumab Rituximab Belinostat Pembrolizumab Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Recruiting
NCT01956812 Phase III Y90 clivatuzumab tetraxetan Gemcitabine Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer (PANCRIT-1) Terminated
NCT02506959 Phase II Dexamethasone Busulfan + Melphalan Pyridoxine Panobinostat Palifermin Gemcitabine Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma Recruiting
NCT02555657 Phase III Pembrolizumab Eribulin Gemcitabine Vinorelbine Capecitabine Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) Active, not recruiting
NCT01532687 Phase II Gemcitabine Gemcitabine + Pazopanib Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting
NCT02551718 Phase I Bosutinib Irinotecan romidepsin Busulfan Melphalan Nilotinib Crizotinib Cytarabine Mitoxantrone Dasatinib Pazopanib Paclitaxel Clofarabine Hydroxyurea Tretinoin Carfilzomib Nelarabine Bexarotene Pentostatin Everolimus Cabozantinib Mercaptopurine Methotrexate Cladribine Thioguanine Daunorubicin Ponatinib Etoposide Afatinib Gefitinib Gemcitabine Regorafenib Arsenic trioxide Trametinib Imatinib Erlotinib Dabrafenib Decitabine Axitinib Azacitidine Ruxolitinib Fludarabine Lapatinib Ceritinib Sirolimus Sorafenib Lomustine Sunitinib Cabazitaxel Temsirolimus Topotecan Bortezomib Pralatrexate High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia Recruiting
NCT01610206 Phase II Gemcitabine + Pazopanib Gemcitabine A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer Active, not recruiting
NCT01935947 Phase II Gemcitabine Azacitidine + Entinostat Docetaxel + Irinotecan + Pemetrexed Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer Terminated
NCT02446600 Phase III Paclitaxel Doxorubicin Gemcitabine Carboplatin Olaparib Cediranib Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting
NCT03191786 Phase III Atezolizumab Gemcitabine Vinorelbine A Study of Atezolizumab Compared With Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Containing Therapy Recruiting
NCT02492711 Phase III Vinorelbine Capecitabine Gemcitabine Trastuzumab Eribulin MGAH22 Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer Recruiting
NCT02079636 Phase I LY3023414 Abemaciclib Gemcitabine Pemetrexed Ramucirumab A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) Active, not recruiting
NCT02422381 Phase Ib/II Gemcitabine Pembrolizumab MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
NCT03697564 FDA approved Cabiralizumab + Gemcitabine + Nivolumab Gemcitabine Nivolumab + Cabiralizumab + Gemcitabine Versus Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial). Not yet recruiting
NCT02009449 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin nab-paclitaxel A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Active, not recruiting
NCT02620865 Phase Ib/II Paclitaxel Aldesleukin Oxaliplatin Sargramostim Gemcitabine Fluorouracil + Leucovorin Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Active, not recruiting
NCT03057106 Phase II Cisplatin Gemcitabine Carboplatin Durvalumab + Tremelimumab Pemetrexed Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC Active, not recruiting
NCT03259503 Phase Ib/II Busulfan Olaparib Vorinostat Palifermin Gemcitabine Melphalan Dexamethasone Pyridoxine Rituximab Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas Not yet recruiting
NCT02595892 Phase II VX-970 Gemcitabine Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting
NCT03257267 Phase III Irinotecan Gemcitabine Vinorelbine Pemetrexed Cemiplimab Topotecan Study of REGN2810 in Adults With Cervical Cancer Recruiting
NCT03056599 Gemcitabine Interferon alfa-2b Doxorubicin Pembrolizumab Eribulin interferon gamma Ipilimumab Trabectedin Aldesleukin Bortezomib Docetaxel Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma Recruiting
NCT02589145 Phase Ib/II Lenalidomide Pyridoxine Dexamethasone Busulfan + Melphalan Enoxaparin Rituximab Gemcitabine Vorinostat Palifermin Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype Active, not recruiting
NCT02309177 Phase I Carboplatin Gemcitabine Nab-paclitaxel + Nivolumab Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer Completed
NCT03607643 Phase Ib/II Temozolomide Bevacizumab + FOLFIRINOX Bevacizumab + Cannabidiol + FOLFIRINOX Bortezomib Bortezomib + Cannabidiol Cannabidiol + Gemcitabine Cannabidiol + Temozolomide Gemcitabine A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies Not yet recruiting
NCT02981342 Phase II Capecitabine Abemaciclib Gemcitabine Abemaciclib + LY3023414 Abemaciclib + Galunisertib A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma Active, not recruiting
NCT02331251 Phase Ib/II Vinorelbine Pembrolizumab Irinotecan Doxorubicin Gemcitabine Docetaxel nab-paclitaxel Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) Terminated
NCT02701673 Phase Ib/II Azacitidine Pyridoxine Gemcitabine Belinostat Busulfan Melphalan Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma Withdrawn
NCT02142738 Phase III Cisplatin Paclitaxel Carboplatin Gemcitabine Pembrolizumab Pemetrexed Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) Active, not recruiting
NCT03734029 Phase III DS-8201a nab-paclitaxel Capecitabine Paclitaxel Gemcitabine Eribulin DS-8201a Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] Recruiting
NCT02409355 Phase III Carboplatin Cisplatin Gemcitabine Atezolizumab A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer Terminated
NCT02101775 Phase II Gemcitabine MK-1775 + Gemcitabine Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting
NCT01506973 Phase Ib/II Hydroxychloroquine Gemcitabine A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer Active, not recruiting